Shots:

• RedHill in collaboration with NIAID will evaluate RHB-107 in non-clinical studies to determine its activity against SARS-CoV-2. The agreement will facilitate the pre-clinical evaluation of RHB-107 as a treatment for COVID-19
• Additionally- RedHill is evaluating opaganib (Yeliva- ABC294640) against COVID-19. On Apr 17- the company unveils about the compassionate use of Opaganib is underway in Israel- with several patients treated to date and preliminary positive outcomes
• RHB-107 is a serine protease inhibitor active against trypsins and other related serine proteases- being evaluated in 300+ people across 10 clinical studies- including two completed P-II studies in oncology patients and multiple P-I studies in healthy volunteers and oncology patients

Click here ­to­ read full press release/ article | Ref: RedHill | Image: Twitter